Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-06-17

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)

View source ↗

Summary

FDA approved a supplemental application for buprenorphine and naloxone by Actavis Pharma, Inc. This approval updates the product's labeling and/or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)